コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 irus (CMV) infection and decreased by use of calcium blockers.
2 ed with ganciclovir who are not treated with calcium blockers.
3 by stratifying patients according to use of calcium blockers.
4 mM Ba2+ that were relatively insensitive to calcium blockers.
5 ation of cyclosporin A (CSA), phenytoin, and calcium blockers.
6 nsin-converting enzyme (ACE) inhibitors, and calcium blockers are commonly used for the treatment of
7 tinct drug effects of sodium, potassium, and calcium blockers, but also reveals subtle differences am
8 ibitor or receptor blocker, beta-blocker, or calcium blocker had no significant effect on survival.
10 CoA reductase inhibitors, and the effects of calcium blockers in preventing TxCAD might have an immun
11 an alternative target anti-MCL therapy, and calcium blockers may be combined with bortezomib to over
12 en ganciclovir and placebo were compared: no calcium blockers (n=53), 32+/-11% (n=28) for ganciclovir
13 versus 62+/-16% (n=25) for placebo (P<0.03); calcium blockers (n=68), 50+/-14% (n=33) for ganciclovir
15 howed an increased sensitivity to the L-type calcium blocker nifedipine; SA node preparations stopped
16 luence of a calcium agonist (BAY K 8644) and calcium blockers on (+)- and (-)-epibatidine-induced ant
17 rolide antibiotics (OR = 0.40, P = .03), and calcium blockers (OR = 0.43, P = .03) were associated wi
18 ed by calcium blockers, the combination of a calcium blocker (perillyl alcohol) with bortezomib suppr
19 atment with low doses of clinically approved calcium blockers should be considered as an option to sl